⁸⁹Zr-Df-IAB22M2C

DRUG2 trials

Sponsors

ImaginAb, Inc., Nektar Therapeutics

Conditions

Metastatic MelanomaMetastatic Solid TumorsPositron-Emission Tomography

Phase 1

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

WithdrawnNCT04955262

Nektar TherapeuticsMetastatic Melanoma

Start: 2019-08-31End: 2022-01-31Updated: 2021-07-08

Phase 2

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

CompletedNCT03802123

ImaginAb, Inc.Metastatic Solid Tumors, Positron-Emission Tomography

Start: 2018-12-18End: 2022-07-18Updated: 2024-07-09

Related Papers

Non-invasive characterization of intratumoral CD8+ T cells using standard-of-care (SOC) CT and ⁸⁹Zr-crefmirlimab berdoxam PET (CD8-PET) radiomic signature in solid tumors.

Journal of Clinical Oncology2026-05-27

Predicting immunotherapy response in advanced solid tumors using quantitative imaging features from CD8 PET/CT exams.

Journal of Clinical Oncology2025-05-28

Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy.

Journal of Clinical Oncology2024-01-291 citations

1281 Prediction of response to immunotherapy using machine learning and tumor kinetic modeling incorporating CD8 PET imaging analysis

Regular and Young Investigator Award Abstracts2023-10-31

CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.

Journal of Clinical Oncology2023-06-013 citations

Abstract 3577: A first assessment of CD8-PET/CT with 89Zr-Crefmirlimab as predictive biomarker for response to standard of care immunotherapy in patients with solid tumors

Cancer Research2023-04-041 citations

1472 Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy

2022-11-011 citations